Tadalafil, a phosphodiesterase type 5 inhibitor, restores urethra and detrusor function in the initial phase of diabetes in rats

2019 ◽  
Vol 11 (4) ◽  
pp. 241-247 ◽  
Author(s):  
Daisuke Gotoh ◽  
Kazumasa Torimoto ◽  
Hirotaka Iwasaki ◽  
Takashi Iwamoto ◽  
Yosuke Morizawa ◽  
...  
Keyword(s):  
Initial Phase ◽  
Phosphodiesterase Type 5 Inhibitor ◽  
Detrusor Function ◽  
Phosphodiesterase Type

scholarly journals Tadalafil, a phosphodiesterase type 5 inhibitor, improves bladder blood supply and restores the initial phase of lower urinary tract dysfunction in diabetic rats

2017 ◽  
Vol 37 (2) ◽  
pp. 666-672 ◽  
Author(s):  
Daisuke Gotoh ◽  
Kazumasa Torimoto ◽  
Yoshihiro Tatsumi ◽  
Shunta Hori ◽  
Atsushi Yamada ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Blood Supply ◽  
Initial Phase ◽  
Lower Urinary Tract ◽  
Diabetic Rats ◽  
Lower Urinary Tract Dysfunction ◽  
Phosphodiesterase Type 5 Inhibitor ◽  
Phosphodiesterase Type ◽  
Lower Urinary

1202: Long-Term Phosphodiesterase Type 5 Inhibitor Therapy Reduces Priapic Activity in Transgenic Sickle Cell Mice

2006 ◽  
Vol 175 (4S) ◽  
pp. 387-387 ◽  
Author(s):  
Trinity J. Bivalacqua ◽  
Hunter C. Champion ◽  
Warren Mason ◽  
Arthur L. Burnett
Keyword(s):  
Sickle Cell ◽  
Inhibitor Therapy ◽  
Phosphodiesterase Type 5 Inhibitor ◽  
Phosphodiesterase Type

scholarly journals The blue pill (sildenafil) and its descendants: an overview

2017 ◽  
Vol 30 (3) ◽  
pp. 129-133
Author(s):  
Tomasz Krzanowski ◽  
Lila Dabkowska ◽  
Monika Wujec ◽  
Ewa Kedzierska
Keyword(s):  
Erectile Dysfunction ◽  
Current Medical ◽  
Medication Treatment ◽  
Phosphodiesterase Type 5 Inhibitor ◽  
Sexuality Study ◽  
The World ◽  
Severity Of The Disease ◽  
Phosphodiesterase Type ◽  
Medical Guidelines ◽  
Active Substances

AbstractAn increasing number of men around the world suffer from erectile dysfunction (ED). Indeed, according to the sexuality study conducted by Professor Izdebski, 1 out of 10 men in Poland suffers from ED. The problem is found among men of any age, however, 60% of all patients are between 40 and 60 years old, thus in their prime, and who still want to fully enjoy life. Not only do the effects of ED affect a man, but they have influence on his relationship and partner as well. In spite of a growing awareness within society, the problem remains perceived as embarrassing, which leads patients to treat themselves on their own, delaying a visit to their doctors. Meanwhile, in many cases, ED may be the first symptom of more serious diseases, such as diabetes, or result from the sideeffects of applied drugs. A breakthrough in the oral medication treatment of ED was observed when a new phosphodiesterase type 5 inhibitor (PDE-5-inhibitor) - sildenafil citrate (Viagra®) - was introduced. Nowadays, 5 active substances from this group are being applied. The current medical guidelines recommend PDE-5 inhibitors as the firstline therapy for most men with ED, irrespective of the cause and severity of the disease. Recently, sildenafil at the dose of 25 mg came into the market without prescription. This paper presents an overview and update of the PDE-5 inhibitors.

Combination of BAY 60-4552 and Vardenafil Exerts Proerectile Facilitator Effects in Rats With Cavernous Nerve Injury: A Proof of Concept Study for the Treatment of Phosphodiesterase Type 5 Inhibitor Failure

2011 ◽  
Vol 60 (5) ◽  
pp. 1020-1026 ◽  
Author(s):  
Alexandra Oudot ◽  
Delphine Behr-Roussel ◽  
Sarah Poirier ◽  
Peter Sandner ◽  
Jacques Bernabé ◽  
...  
Keyword(s):  
Nerve Injury ◽  
Proof Of Concept ◽  
Cavernous Nerve ◽  
Concept Study ◽  
Phosphodiesterase Type 5 Inhibitor ◽  
Phosphodiesterase Type ◽  
Cavernous Nerve Injury
Sign in / Sign up

Export Citation Format

Share Document